sclareol has been researched along with Cirrhosis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, X; Liang, G; Ren, J; Shi, Q; Tu, Y; Wang, Y; Wei, J; Ying, H; Zhang, J; Zhang, Y; Zhou, L | 1 |
| Liang, G; Luo, W; Shan, P; Wang, M; Wang, Y; Wu, G; Xu, D; Yang, N; Zou, C | 1 |
| Bao, YY; Ge, MX; He, HW; Lu, ZN; Niu, WX | 1 |
3 other study(ies) available for sclareol and Cirrhosis
| Article | Year |
|---|---|
Sclareol ameliorates hyperglycemia-induced renal injury through inhibiting the MAPK/NF-κB signaling pathway.
Topics: Animals; Cytokines; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Diterpenes; Fibrosis; Glucose; Hyperglycemia; Inflammation; Kidney; Mice; Mitogen-Activated Protein Kinases; NF-kappa B; Signal Transduction | 2022 |
Sclareol attenuates angiotensin II-induced cardiac remodeling and inflammation via inhibiting MAPK signaling.
Topics: Angiotensin II; Animals; Fibrosis; Heart Failure; Hypertension; Inflammation; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; Myocardium; Myocytes, Cardiac; Ventricular Remodeling | 2023 |
Sclareol attenuates liver fibrosis through SENP1-mediated VEGFR2 SUMOylation and inhibition of downstream STAT3 signaling.
Topics: Animals; Fibrosis; Hepatic Stellate Cells; Liver; Liver Cirrhosis; Mice; Rats; Signal Transduction; Sumoylation | 2023 |